Tags

Type your tag names separated by a space and hit enter

Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
CNS Neurol Disord Drug Targets. 2017; 16(2):169-175.CN

Abstract

BACKGROUND

Creatine is an antioxidant agent that showed neuroprotective effects in animal models of Parkinson's disease (PD). Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease. Therefore, many clinical trials evaluated the efficacy of creatine for patients with PD. The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of Creatine for patients with PD.

METHODS

We followed PRISMA statement guidelines during the preparation of this systematic review and meta-analysis. A computer literature search for PubMed, EBSCO, web of science and Ovid Midline was carried out. We included RCTs comparing creatine with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, and UPDRS III were pooled as mean difference (MD) between two groups from baseline to the endpoint. Statistical heterogeneity was assessed by visual inspection of the forest plot and measured by chi-square and I square tests.

RESULTS

Three RCTs (n=1935) were included in this study. The overall effect did not favor either of the two groups in terms of: UPDRS total score (MD 1.07, 95% CI [3.38 to 1.25], UPDRS III (MD 0.62, 95% CI [2.27 to 1.02]), UPDRS II (MD 0.03, 95% CI [0.81 to 0.86], or UPDRS I (MD 0.03, 95% CI [0.33 to 0.28]).

CONCLUSION

Current evidence does not support the use of creatine for neuroprotection against PD. Future well-designed, randomized controlled trials are needed.

Authors+Show Affiliations

Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Medical Research Group of Egypt, Cairo, Egypt.Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Postal Code: 44519, Egypt.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

27823574

Citation

Attia, , et al. "Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease." CNS & Neurological Disorders Drug Targets, vol. 16, no. 2, 2017, pp. 169-175.
Attia , Ahmed H, Gadelkarim M, et al. Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. CNS Neurol Disord Drug Targets. 2017;16(2):169-175.
Attia, ., Ahmed, H., Gadelkarim, M., Morsi, M., Awad, K., Elnenny, M., Ghanem, E., El-Jaafary, S., & Negida, A. (2017). Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. CNS & Neurological Disorders Drug Targets, 16(2), 169-175. https://doi.org/10.2174/1871527315666161104161855
Attia , et al. Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. CNS Neurol Disord Drug Targets. 2017;16(2):169-175. PubMed PMID: 27823574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. AU - Attia,, AU - Ahmed,Hussien, AU - Gadelkarim,Mohamed, AU - Morsi,Mahmoud, AU - Awad,Kamal, AU - Elnenny,Mohamed, AU - Ghanem,Esraa, AU - El-Jaafary,Shaimaa, AU - Negida,Ahmed, PY - 2016/05/17/received PY - 2016/10/09/revised PY - 2016/10/20/accepted PY - 2016/11/9/pubmed PY - 2018/5/16/medline PY - 2016/11/9/entrez KW - Neuroprotection KW - Parkinson's disease SP - 169 EP - 175 JF - CNS & neurological disorders drug targets JO - CNS Neurol Disord Drug Targets VL - 16 IS - 2 N2 - BACKGROUND: Creatine is an antioxidant agent that showed neuroprotective effects in animal models of Parkinson's disease (PD). Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease. Therefore, many clinical trials evaluated the efficacy of creatine for patients with PD. The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of Creatine for patients with PD. METHODS: We followed PRISMA statement guidelines during the preparation of this systematic review and meta-analysis. A computer literature search for PubMed, EBSCO, web of science and Ovid Midline was carried out. We included RCTs comparing creatine with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, and UPDRS III were pooled as mean difference (MD) between two groups from baseline to the endpoint. Statistical heterogeneity was assessed by visual inspection of the forest plot and measured by chi-square and I square tests. RESULTS: Three RCTs (n=1935) were included in this study. The overall effect did not favor either of the two groups in terms of: UPDRS total score (MD 1.07, 95% CI [3.38 to 1.25], UPDRS III (MD 0.62, 95% CI [2.27 to 1.02]), UPDRS II (MD 0.03, 95% CI [0.81 to 0.86], or UPDRS I (MD 0.03, 95% CI [0.33 to 0.28]). CONCLUSION: Current evidence does not support the use of creatine for neuroprotection against PD. Future well-designed, randomized controlled trials are needed. SN - 1996-3181 UR - https://www.unboundmedicine.com/medline/citation/27823574/Meta_Analysis_of_Creatine_for_Neuroprotection_Against_Parkinson's_Disease_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1871-5273&volume=16&issue=2&spage=169&aulast= DB - PRIME DP - Unbound Medicine ER -